In summary, 273 cases (12%) were grouped into AML with recurrent genetic rearrangements, 476 cases (22%) into AML with gene mutations (NPM1 or biallelic CEBPA), and 90 cases (4%) into other rare rearrangements. This evidence concerns the gene CEBPA and acute myeloid leukemia.